
    
      Eligible subjects will provide written informed consent after which demographic and baseline
      clinical data will be recorded.

      Collection of whole blood and urine samples will be performed at one or more clinic visits
      from pregnant women carrying a single fetus with no known fetal abnormalities.

      Interim study visits will continue every 14 days [+/- 3 days] until the subject either: 1)
      reaches 37 0/7 weeks' gestation, 2) develops Pre-E, 3) delivers, or 4) is lost to follow-up.

      In addition, a group of pregnant women diagnosed with Pre-E will be enrolled as positive
      control cases.
    
  